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Abstract
Background: Electron beam computed tomography (EBCT) is a method for measuring coronary
calcification and has been promoted as a possible non-invasive screening/diagnostic tool for
coronary artery disease (CAD). Our objective was to carry out a systematic review and meta-
analysis of EBCT for the screening of asymptomatic patients and the diagnosis of symptomatic
patients for CAD.
Methods: Studies were identified from the PUBMED, MEDLINE, EMBASE, Current Contents,
INAHTA and Cochrane Collaboration databases. We identified studies published in English
evaluating EBCT using: (1) a prospective design among asymptomatic patients where CAD was
measured in terms of clinical outcomes (e.g. myocardial infarction, death, revascularization); and
(2)a cross-sectional design among symptomatic patients where CAD was measured by coronary
angiography. We compared the risk of CAD in EBCT score categories defined as low (0–10),
moderate (11–400) and high (>400). A hierarchical meta-analysis was used to pool risk ratios
comparing categories across studies.
Results: We identified 9 studies of asymptomatic patients and 10 studies of symptomatic patients.
In both types of studies, we found variability in EBCT category distribution and risk of CAD within
categories. For studies of asymptomatic patients we estimated the following risk ratios (95%
credible intervals): moderate versus low 3.5 (2.4, 5.1) and high versus low 9.9 (5.3, 17.6). Similar
results were obtained for studies of symptomatic patients. Ratios comparing the risk of no CAD
among symptomatic patients were as follows: moderate versus low 0.5 (0.3, 0.8) and high versus
low 0.12 (0.05, 0.2).
Conclusion: Increasing EBCT scores indicate higher risk for CAD in both asymptomatic and
symptomatic patients. In general, asymptomatic patients with EBCT scores in the high category can
perhaps be considered for preventive medical therapy and risk factor modification. Symptomatic
patients with EBCT scores in the low category can perhaps, at least temporarily, avoid invasive
coronary angiography. However, the non-uniform quality of studies and the lack of availability of
individual-level data preclude the extension of our results to individual patients.
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Despite tremendous advances in the prevention and treat-
ment of coronary artery disease (CAD), diagnosis and
prognosis remain difficult issues. The measurement of
coronary calcium deposits has been proposed as a new
non-invasive diagnostic tool. Calcium deposition can be
quantified non-invasively at a very early stage by electron
beam computed tomography (EBCT) using the Agatston
method [1]. EBCT scanners are not as versatile as multide-
tector slice computed tomography (MDCT), but their
technological simplicity without moving parts permits
more rapid examinations at lower costs [2]. While MDCT
is also widely used for the assessment of coronary cal-
cium, the current article focuses on evaluating EBCT. A
more detailed examination of EBCT versus MDCT tech-
nology appears in a recent scientific statement from the
American Heart Association [2].
While the measurement of coronary calcification using
EBCT has emerged as a promising screening and diagnos-
tic tool for CAD, there is concern about widespread dis-
semination of this technology into routine clinical
practice before adequate evaluation. Herein we provide a
systematic review of the literature on the efficacy of EBCT
with separate analyses for both asymptomatic and symp-
tomatic patients. We improve upon previous meta-analy-
ses by: (1) updating previous conclusions with results of
recent articles; (2)providing quantitative support for
guidelines defining low, moderate and high EBCT scores
[3] for both asymptomatic and symptomatic patients; and
(3) providing risk ratios for comparing both positive and
negative predictive values between low, moderate
and high EBCT score categories.
Methods
Data sources and searches
We searched the following electronic literature databases:
PUBMED, MEDLINE, EMBASE, Current Contents,
INAHTA and Cochrane Collaboration. Search terms were
'electron beam tomography' OR 'electron beam' OR 'EBT'
OR 'EBCT' OR 'ultrafast' AND 'coronary artery disease' OR
'coronary blood vessel' OR 'coronary' AND 'calcification'
OR 'calcium'. Bibliographies of identified articles were
searched further. We included studies that were published
before 31 July 2006.
Study selection, data extraction and quality assessment
We required that studies: (1) were published in English;
(2) recruited consecutive patients; (3) followed a prospec-
tive design for studies of asymptomatic patients; and
(4)were designed such that both EBCT and coronary ang-
iography were carried out within 3 months in studies of
symptomatic patients. From each study we extracted
details of the method of recruitment, inclusion/exclusion
criteria, length of follow-up and percentage of completed
follow-up (for prospective studies), details of the EBCT
protocol, EBCT categories, distribution of patients across
EBCT categories, outcome definition, percentage of
patients with the outcome of interest in each EBCT cate-
gory and aggregate results on covariates such as age, sex,
smoking, diabetes, hypertension, hypercholesterolemia
and history of CAD. Data were extracted by two of the
authors (KC and ND). Relevant items from the Standards
for Reporting of Diagnostic Accuracy (STARD) guidelines
were used to evaluate the quality of individual articles [4].
Data synthesis and analysis
Defining categories on the EBCT scale
There are no standardized EBCT cut-offs, which makes
comparative analyses difficult. One guideline [3] has sug-
gested the following cut-offs: 0 (very low), 1–10 (low),
11–100 (moderate), 101–400 (moderately high), >400
(high). For each selected study, we elected to
transform the reported categories as closely as possible
into one of three standardized categories: low (0–10),
moderate (11–400) and high (>400). The lowest and
highest categories in a given study were always
classified as low and high, respectively. When there was
uncertainty about the EBCT classification we carried out
sensitivity analyses by placing the category into the adja-
cent group.
Hierarchical meta-analysis comparing predictive values between 
EBCT categories
For each category we calculated the probability of the out-
come (positive predictive value) and the probability of the
absence of the outcome (negative predictive value). Given
the variability in predictive values across studies, we
decided that only the ratios comparing predictive values
between categories could reasonably be pooled across
studies. This was done by means of a hierarchical meta-
analysis [5]. A separate model was fit for each pair of
categories that were compared. We chose to compare
categories using risk ratios, rather than the commonly
used odds ratio, for greater interpretability [5]. Non-
informative prior distributions were used for all parame-
ters, thus the results reflect the information in the
observed data. We reported the posterior median and
95% credible intervals for the parameters of interest.
The models were implemented using WinBUGS software.
A copy of the program is available from the first author
upon request.
Results
The results of the literature search are summarized in
Figure 1. From 745 initial studies, we identified 9 prospec-
tive studies of asymptomatic patients [6-14] and 10 cross-
sectional studies of symptomatic patients [15-24].Page 2 of 17
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Flowchart summarizing study selectionigure 1
Flowchart summarizing study selection.
Potentially relevant articles 
identified using MEDLINE, 
EMBASE and Current 
Contents databases (n=745)
Articles retrieved for 
detailed evaluation (n=69) 
Longitudinal studies 
of asymptomatic 
patients (n=30) 
Articles excluded (n=676): 
Outcomes not of interest (n=307) 
Studies unrelated to CAD (n=122) 
EBCT not used (n=112) 
Articles identified as reviews (n=108) 
Post surgery (n=27) 
Cross-sectional 
studies of 
symptomatic 
patients (n=39) 
Potentially 
appropriate articles 
(n=19) 
Potentially 
appropriate articles 
(n=14) 
Duplicate studies (n=25)Duplicate studies (n=11)
Articles included in 
report (n=9) 
Articles included in 
report (n=10) 
Articles excluded (n=10) 
Retrospective studies (n=7) 
Studies only looking at part 
of EBCT scale (n=2) 
Unable to extract data from 
article (n=1) 
Articles excluded (n=4) 
Results presented by individual 
artieries/segments (n=2) 
Can’t extract data on CAD 
negative patients (n=1) 
>3 months gap between CAG 
and EBCT (n=1)
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Table 1: Quality of studies of asymptomatic subjects
Item Value
Wong et 
al. [6]
Arad et al. 
[11]
Raggi et al. 
[7]
Kondos et 
al. [8]
Shaw et al. 
[9]
Greenland 
et al. [10]
Taylor et 
al. [12]
Vlie-
genthart et 
al. [13]
LaMonte 
et al. [14]
Patient 
recruit-ment
1: Self referred 2 NR 2 1 2 1 3 3 2
2: Clinician referred
3: Population sample
Exclusion 
criteria
1: Did not exclude history of 
heart disease
2 2 NR 2 2 2 2 2 2
2: Excluded history of heart 
disease
Outcome 
defined
1: All cause mortality 2 2 3 3 1 3 3 2 2
2: Coronary outcomes* and 
revascularization
3: Coronary outcomes* only
EBCT 
categories
1: Quartiles or pre-selected cut-
offs
1 1 2 1 1 1 1 1 1
2: Age – sex adjusted
Outcome 
extraction 
blinded to 
EBCT score
1: No 2 2 2 2 2 2 2 2 2
2: Yes
Demographic 
characteristics, 
risk factors
NR: Not reported 1 1 1 1 1 1 1 1 1
1: Reported (see Table 3)
Percentage 
follow-up
NR: Not reported NR 1 1 1 1 1 1 1 1
1: Yes (see Table 4)
Adjusted 
results 
available
1: Yes but cannot be used in 
meta-analysis
1 1 3 2 3 3 2 3 3
2: Yes at single cut-off and can be 
used in meta-analysis.
3: Yes at multiple cut-offs and can 
be used in meta-analysis
Total Maximum: 17 11 11 14 13 13 14 15 15 14
*Coronary outcomes: angina, myocardial infarction, coronary death.
BMC Medicine 2007, 5:35 http://www.biomedcentral.com/1741-7015/5/35Quality of individual studies
Tables 1 and 2 summarize the quality of each study accord-
ing to relevant criteria from the STARD guidelines [4]. Most
studies of asymptomatic patients excluded patients with a
history of heart disease or with a suspected myocardial inf-
arction (MI). However, there was variability in the source
population: in some studies patients were self-referred,
while in others they were referred by a physician or identi-
fied during a routine annual examination. These studies
reported the risk of hard outcomes (unstable angina, MI,
stroke, coronary death, all-cause mortality) and sometimes
also included the softer cardiac outcome of coronary revas-
cularization (Table 3) [14,11]. Most studies of symptomatic
patients recruited patients with MI or suspected MI, who
would normally be considered candidates for angiography.
All of these studies defined coronary disease as the presence
of at least 50% coronary stenosis based on angiographic
findings. A summary of the demographic and clinical char-
acteristics from the selected studies is given in Table 4. There
was no clear difference in the distribution of age, sex, smok-
ing and history of CAD among studies of asymptomatic and
symptomatic patients based on the reported aggregate data.
The percentage of patients with hypertension and diabetes
was somewhat higher in studies of symptomatic patients
compared with asymptomatic patients.
EBCT protocol
Eighteen studies followed the Agatston method for scor-
ing; only one study followed the Erlanger method for
scoring [17]. While all studies used a threshold of greater
than 130 Hounsfield units to identify a calcified lesion,
there was wide variability in the minimum area in which
the signal had to be observed ranging from 0.44 to 1.02
mm2. The width of each slice was 3 mm in all studies
except one, which used 6 mm slices[10]. The scan time per
rotation was 100 ms in all studies. The percentage of the
R-R interval to which the scan acquisition trigger was set
was typically 80%.
Results from prospective studies of asymptomatic patients
Distribution of EBCT categories and risk of outcome
The distributions of EBCT scores as reported in each study
are given in Table 5 along with the summary categoriza-
tion from low to high. The cut-offs reported by individual
studies varied greatly, although most studies reported the
number of patients with a calcium score of zero. The prob-
ability of the outcome increased with increasing EBCT
score in all studies (Figure 2 and Table 5). Given the con-
siderable variation between studies in the risk of develop-
ing CAD (see Table 5), we concluded that it was not
clinically meaningful to pool predictive values across
studies. We concentrated instead on pooling the ratios of
moderate- or high-risk categories to the baseline low cate-
gory from each study.
Meta-analysis
A forest plot of the individual and overall risk ratios is
given in Figure 3. The pooled risk ratios comparing posi-
tive predictive values across EBCT categories were statisti-
cally significant. A forest plot of the risk ratios of the
negative predicted values is given in Figure 4. The overall
risk ratios comparing the three categories were all close to
1, indicating that despite the fact that the negative predic-
tive values were high the EBCT categorization was not very
useful for identifying patients unlikely to have CAD.
Results from cross-sectional studies of symptomatic 
patients
Distribution of EBCT categories and risk of outcome
The distribution of EBCT scores in each study is given in
Table 6 along with the summary categorization from low
to high. As in the case of studies of asymptomatic patients,
there was variation in the reported cut-offs, the distribu-
tion of EBCT scores and the risk of CAD in each EBCT cat-
egory. The negative predictive value (probability of no
CAD) corresponding to a calcium score of zero ranged
from 0.58 to 0.92 in the individual studies.
Meta-analysis
The results of the meta-analyses are presented in Figures 5
and 6. Once again there was a statistically significant dif-
ference in the positive predictive values in the low cate-
gory compared with the other two categories. In
particular, the pooled risk ratios suggest that a sympto-
matic subject with a low score has approximately one-
quarter of the risk of having significant angiographic cor-
onary stenosis than the moderate/high categories. This
would mean that if the average patient in the moderate/
high category had an 80% risk of CAD, the average patient
in the low category would have a 20% risk of CAD. The
overall risk ratios comparing negative predictive values
were significantly different from 1. In particular, negative
predictive values in the low category were much higher
than in the other two categories suggesting that a sympto-
matic subject with a low score has a very small likelihood
of having coronary stenosis. For three studies [19,22]
there was ambiguity in determining the simplified classi-
fication of the EBCT score category. However, repeating
the meta-analysis following a reclassification of these cat-
egories did not affect our final results.
Discussion
We have carried out a systematic review and meta-analysis
of the published literature on the screening and diagnosis
of CAD using EBCT. We identified two different types of
studies: (1) 9 prospective studies of asymptomatic
patients evaluating the predictive validity of EBCT for a
mixture of hard outcomes (unstable angina, MI, stroke,
coronary death, all-cause mortality) and revasculariza-
tion; and (2) 10 cross-sectional studies of symptomaticPage 5 of 17
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Table 2: Quality of studies of symptomatic subjects
Item Value
Budoff et 
al. [15]
Baumgart 
et al. [16] Seese et 
al. [17]
Yao et al. 
[18]
Chen et al. 
[19]
Bielak et 
al. [20]
Hosoi et 
al. [21]
Budoff et 
al. [22]
Almeda et 
al. [23] Knez et al. 
[24]
Patient 
recruitment
NR: Not reported 1 1 1 1 1 1 1 1 NR 1
1: Undergoing CAG for 
clinical indications
Exclusion 
criteria
NR: Not reported NR 1 NR NR 1 1 NR 1 NR NR
1: History of CAD/
revascularization
Outcome 
defined
1: No 2 2 2 2 2 2 2 2 2 2
2: Yes
EBCT 
categories
1: Quartiles or pre-selected 
cut-offs
1 1 1 1 1 1 1 1 1 1
2: Age – sex adjusted
Outcome 
measurement 
blinded to EBCT 
score
1: No NR 2 NR NR 2 NR 2 2 NR 2
2: Yes
Demographic 
characteristics
NR: Not reported 1 1 1 NR 1 1 1 1 1 1
1: Reported
Risk factors NR : Not reported NR NR NR NR 1 1 1 NR 1 1
1: Reported (see Table 3)
Adjusted results 
available
1: Yes but cannot be used in 
meta-analysis
1 NR NR NR 2 3 1 2 2 NR
2: Yes at single cut-off and 
can be used in meta-analysis.
3: Yes at multiple cut-offs 
and can be used in meta-
analysis
Total Maximum: 13 6 8 5 4 11 10 9 10 7 8
BMC Medicine 2007, 5:35 http://www.biomedcentral.com/1741-7015/5/35patients evaluating the concurrent validity of EBCT for
coronary stenosis as measured by coronary angiography.
The risk of coronary events or angiographically confirmed
CAD increased consistently with increasing EBCT scores
in both types of studies.
Our results provide quantitative support for the cut-offs
proposed by Rumberger et al. [3] to determine low-, mod-
erate- and high-risk categories of EBCT scores. These cut-
offs have since been used by a number of studies for
reporting the validity of EBCT [9,11,13,21,23]. Similar
cut-offs have been used in two earlier meta-analyses of
studies of asymptomatic patients, including the recently
published ACCF/AHA Clinical Expert Consensus Docu-
ment [25,26]. These cut-offs were determined based on a
qualitative review of the literature. For example, an EBCT
score of 0 was assumed to be associated with a risk of 5%
or less of CAD, while a score of 400 or more was assumed
to be associated with a risk of 90% or more of CAD. Based
on the studies we have identified, these assumptions seem
to be reasonable estimates of the risk of coronary stenosis
in symptomatic patients, but not of prognostic risk in
asymptomatic patients. Furthermore, we have found that
even among studies of symptomatic patients there is con-
siderable variability in these values. Nonetheless, our
analyses have shown that the cut-offs proposed by Rum-
berger et al. [3] are clinically meaningful for classifying the
aggregate patient into categories associated with a monot-
onically increasing risk of an adverse cardiac outcome. For
asymptomatic patients this difference in risk is statistically
significantly different between all categories, while in
symptomatic patients the difference between moderate
and high categories is only of borderline statistical signif-
icance. We found that among asymptomatic patients, neg-
ative predictive values in these same categories were very
high independent of the category threshold, and thus did
not help us to distinguish between categories. Among
symptomatic patients, where the disease prevalence is nat-
urally much higher, negative predictive values were lower.
However, they were significantly higher in the low EBCT
category compared with moderate or high categories.
We cannot comment on the utility of EBCT scores for
individual risk stratification as our results were not
adjusted for age, sex and other known risk factors. There-
fore, while the proposed cut-offs [3] may be useful for
making conclusions about the average patient they
should not be used for individual risk stratification in
light of our knowledge of the age-sex variation in coro-
nary calcium scores [27]. For the average patient, our
results suggest that an asymptomatic patient with a high
EBCT score may benefit from extensive follow-up possi-
bly supported by intensive medical therapy. Similar
conclusions apply to asymptomatic patients classified as
having a moderate EBCT score. In symptomatic patients,
it appears that the average patient with a low EBCT score
may have only a small chance of having coronary stenosis
compared with those with high or moderate scores. Thus,
they could be further evaluated with non-invasive tests
possibly avoiding angiography.
Compared with earlier meta-analyses of asymptomatic
subjects [26,28,25], we found four new articles
[8,13,14,12] and cohorts with longer follow-up for three
previously included articles [10,9,11]. A previous meta-
analysis [25] extrapolated data for individual studies in
order to make them comparable when the reported EBCT
cut-offs were different from the values identified to define
Table 3: Definition of outcomes and length of follow-up in studies of asymptomatic subjects
Study Definition of outcome*
Mean length of follow-up 
(years) Follow-up completed (%)
1. Wong et al. [6] MI, stroke, revascularization 3.3 ---
2. Raggi et al. [7] MI, sudden cardiac death or death 
due to MI
2.7 100%
3. Kondos et al. [8] Death (owing to CHD or 
unknown cause), MI
3.1 64%
4. Shaw et al. [9] All-cause mortality 5 100%
5. Greenland et al. [10] MI or CHD death 7.0 87.5%
6. Arad et al. [11] Coronary death, non-fatal MI, 
CABG, PTCA
4.3 94%
7. Taylor et al. [12] Sudden cardiac death, MI, unstable 
angina
3.0 99.2%
8. Vliegenthart et al. [13] Incident MI, CHD mortality, 
revascularization
3.3 ~100%
9. LaMonte et al. [14] Non-fatal MI or death from 
coronary causes, coronary 
revascularization
3.5 70%
*CABG, coronary artery bypass graft; CHD, coronary heart disease; MI, myocardial infarction; PTCA, percutaneous transluminal coronary 
angioplasty.Page 7 of 17
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use categories that were actually reported and classified
them as closely as possible into low, moderate and high.
Also, in contrast to this earlier meta-analysis [25], we
chose to combine the ratios of predictive values that had
not been adjusted for CAD risk factors in order to permit
a larger sample size for analysis. Although our ratios of
positive predictive values are slightly higher than the val-
ues from this meta-analysis [25], they lead to similar con-
clusions. Similar results were also obtained in a meta-
analysis of six studies of asymptomatic patients published
recently in the ACCF/AHA Clinical Expert Consensus
Document [26]. Compared with the earlier meta-analysis
of symptomatic subjects [29], we have identified one
additional article [17] and added additional information
in two studies [22,1]. Unlike the previous analysis, we
treated the results from one multi-centre trial as coming
from a single study [15]. Furthermore, we divided the 'cal-
cium positive' scores into moderate and high categories.
In our analyses of both types of studies we reported ratios
comparing negative predictive values in addition to those
comparing positive predictive values.
The large number of potentially relevant studies identified
by our literature search reduced to 19 unique studies pro-
viding quantitative information that could be used to
evaluate the utility of EBCT. Thus, despite the large
number of publications about this technology, there is
clearly a paucity of useful information for evaluating it.
The main limitation of our study relates to the quality of
the original publications and their deficiencies in follow-
ing definitive standards for diagnostic publications. Com-
bining information across the identified studies proved
challenging given the lack of a standardized approach for
reporting EBCT scores and the variability in recruitment
methods/population across studies. Very few studies met
more than 80% of the criteria identified by the STARD
guidelines for measuring quality of reporting in diagnos-
tic studies.
We were unable to separate results based on age or gender,
both of which have been shown to have an important
impact on the interpretation of EBCT scores. We were also
unable to estimate the incremental value of EBCT beyond
established risk factors. Both of these limitations were the
Table 4: Summary of demographic characteristics and risk factors
Study
Age mean (SD) 
(years) Male (%) Smokers (%)
Hypertension 
(%) Diabetes (%)
History of 
CAD* (%)
Studies of asymptomatic subjects
1. Wong et al. [6] 64 (--) 76 24 26 5 ---
2. Raggi et al. [7] 52 (9) 50 65 52 15 47
3. Kondos et al. [8] 51 (9) 74 48 20 3 ---
4. Shaw et al. [9] 53 (0.1) 60 40 44 9 69
5. Greenland et al. 
[10]
66 (8) 90 18 41 - ---
6. Arad et al. [11] 53 (11) 71 10 34 6 21
7. Taylor et al. [12] 43 (3) 82 8 29 1 32
8. Vliegenthart et 
al. [13]
71 (6) 43 16 60 12 19
9. LaMonte et al. 
[14]
54 (10) 64 9 18 3 ---
Studies of symptomatic subjects
1. Budoff et al. [15] 56 (12) 64 --- --- --- ---
2. Baumgart et al. 
[16]
54 (9) 79 --- --- --- ---
3. Seese et al. [17] 55 (8) 87 --- --- --- ---
4. Yao et al. [18] --- --- --- --- --- ---
5. Chen et al. [19] 66 (10) 85 53 59 16 32
6. Bielak et al. [20] 56 (11) 76 62 45 13 51
7. Hosoi et al. [21] 63 (-) 67 --- 56 36 ---
8. Budoff et al. [22] 58 (11) 63 --- --- --- ---
9. Almeda et al. 
[23]
60 78 14 51 18 57
10. Knez et al. [24] 62 (10) 78 23 66 22 ---
*CAD, coronary artery disease.Page 8 of 17
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Table 5: EBCT score distribution and positive predicted values in studies of asymptomatic patients
Reported classification Simplified classification
Study EBCT category
Number (%) of 
patients
Number (%) 
with outcome EBCT Category
Number (%) of 
patients
Number (%) 
with outcome
1. Wong et al. [6] 0 398 (42.9) 4 (1.0) Low
1–15 133 (14.3) 1 (0.8) Low 531 (57.2) 5 (0.1)
16–80 134 (14.4) 5 (3.7) Moderate
81–270 131 (14.1) 7 (5.3) Moderate 265 (28.6) 12 (4.5)
271 132 (14.2) 11 (8.3) High 132 (14.2) 11 (8.3)
Total 928 28
2. Raggi et al. [7] 0 292 (46.2) 1 (0.3) Low 292 (46.2) 1 (0.3)
1–99 219 (34.7) 12 (5.5) Moderate
100–400 74 (11.7) 8 (10.8) Moderate 293 (46.3) 20 (6.8)
>400 47 (7.4) 6 (12.8) High 47 (7.4) 6 (7.4)
Total 632 27
3. Kondos et al. [8] 0 1816 (32.2) 5 (0.3) Low 1816 (32.2) 5 (0.3)
>0 3819 (67.8) 53 (1.4) Moderate/high 3819 (67.8) 53 (1.4)
Total 5635 58
4. Shaw et al. [9] 10 5946 (57.3) 62 (1.0) Low 5946 (57.3) 62 (1.0)
11–100 2044 (19.7) 53 (3.0) Moderate
101–400 1432 (13.8) 54 (3.8) Moderate 3476 (33.5) 107 (2.9)
401–1000 623 (6.0) 39 (6.3) High
>1000 332 (3.2) 41 (12.4) High 955 (9.2) 80 (8.4)
Total 10377 249
5. Greenland et al. 
[10]
0 316 (30.7) 14 (4.4) Low 316 (30.7) 14 (4.4)
1–100 321 (31.2) 21 (6.5) Moderate
101–300 171 (16.6) 15 (8.8) Moderate 492 (47.8) 36 (7.3)
301 221 (21.5) 34 (15.4) High 221 (21.5) 34 (15.4)
Total 1029 84
6. Arad et al. [11] 0 1504 (25) 8 (0.5) Low 1504 (25.0) 8 (0.5)
1–99 1973 (25) 20 (1) Moderate
100–399 686 (25) 38 (5.5) Moderate 2659 (50.0) 58 (2.2)
400 450 (25) 63 (14) High 450 (25.0) 63 (14.0)
Total 4613 129
7. Taylor et al. [12] 0 1261 (77.6) 7 (0.6) Low 1381 (85.0) 7 (0.6)
1–9 120 (7.4) 0 (0.0) Moderate
10–44 120 (7.4) 2 (1.7) Moderate 120 (7.4) 2 (1.7)
>44 124 (7.6) 5 (4.0) Moderate/high 124 (7.6) 5 (4.0)
Total 1625 14
8. Vliegenthart et 
al. [13]
0–100 905 (50.4) 7 (0.8) Low 905 (50.4) 7 (0.8)
101–400 425 (23.7) 13 (3.1) Moderate 425 (23.7) 13 (3.1)
401–1000 269 (15.0) 13 (4.5) High
>1000 196 (10.9) 17 (8.7) High 365 (25.9) 30 (8.2)
Total 1795 50
9. LaMonte et al. 
[14]
0 5472 (50.9) 15 (0.3) Low 5472 (50.9) 15 (0.3)
1–38 (Men), 1–16 
(Women)
1760 (16.4) 19 (1.1) Moderate
39–249 (Men), 17–
112 (Women)
1758 (16.4) 62 (3.5) Moderate 3518 (32.8) 81 (2.3)
250(Men), 113 
(Women)
1756 (16.3) 191 (10.9) High 1756 (16.3) 191 (10.9)
Total 10746 287
*CAD, coronary artery disease.
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Distribution of positive predictive values across EBCT score categoriesFigure 2
Distribution of positive predictive values across EBCT score categories.
Low Moderate High
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Studies of Asymptomatic Subjects
EBCT score category
Po
si
tiv
e
 
Pr
e
di
ct
iv
e
 
Va
lu
e
(N=9) (N=8) (N=8)
Low Moderate High Moderate+High
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Studies of Symptomatic Subjects
EBCT score category
Po
si
tiv
e
 
Pr
e
di
ct
iv
e
 
Va
lu
e
(N=11) (N=6) (N=6) (N=5)
BMC Medicine 2007, 5:35 http://www.biomedcentral.com/1741-7015/5/35
Page 11 of 17
(page number not for citation purposes)
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Table 6: EBCT score distribution and positive predictive values in studies of symptomatic subjects
Reported classification Simplified classification
Study EBCT category
Number (%) of 
patients
Number (%) 
with CAD EBCT category
Number (%) of 
patients
Number (%) 
with CAD
Budoff et al. [15] 0 147 (20.7) 23 (15.6) Low 147 (20.7) 23 (15.6)
>0 563 (79.3) 404 (71.8) Moderate/high 563 (79.3) 404 (71.8)
Total 710 427
Baumgart et al. 
[16]
0 32 (56.1) 10 (31.3) Low 32 (56.1) 10 (31.3)
>0 25 (43.9) 19 (76.0) Moderate/high 25 (43.9) 19 (76.0)
Total 57 29
Seese et al. [17] 0 22 (20.6) 4 (18.2) Low 22 (20.6) 4 (18.2)
>0 85 (79.4) 83 (97.7) Moderate/high 85 (79.4) 83 (97.7)
Total 107 87
Yao et al. [18] 0 26 (40.1) 11 (42.3) Low 26 (40.1) 11 (42.3)
>0 38 (59.9) 34 (89.5) Moderate/high 38 (59.9) 34 (89.5)
Total 64 45
Bielak et al. [20] 0 40 (18.8) 1 (2.5) Low
1–9 31 (14.6) 8 (25.8) Low 71 (33.3) 9 (12.7)
10–49 25 (11.7) 6 (24.0) Moderate
50–99 13 (6.1) 7 (53.8) Moderate
100–199 24 (11.3) 17 (70.8) Moderate
200–499 25 (11.7) 21 (84.0) Moderate? 87 (40.8) 51 (58.6)
500 55 (25.8) 52 (94.5) High 55 (25.8) 52 (94.5)
Total 213 112
Chen et al. [19] 0–5 22 (19.0) 2 (9.1) Low 22 (19.0) 2 (9.1)
6–75 17 (14.7) 3 (17.7) Moderate
76–500 29 (15.0) 24 (82.8) Moderate? 46 (29.7) 27 (58.7)
>500 48 (41.4) 45 (93.8) High 48 (41.4) 45 (93.8)
Total 116 74
Hosoi et al. [21] 0 36 (12.8) 7 (19.4) Low 74 (26.3) 29 (39.2)
1–10 38 (13.5) 22 (57.9) Low
11–100 59 (20.9) 39 (66.1) Moderate
101–399 53 (18.8) 41 (77.4) Moderate 112 (39.7) 80 (71.4)
>399 96 (34) 93 (96.9) High 96 (34) 93 (96.9)
Total 282 202
Budoff et al. [22] 0 386 (20.9) 39 (10.1) Low 386 (20.9) 39 (10.1)
1–20 216 (11.7) 60 (27.8) Moderate?
21–80 230 (12.4) 108 (47.0) Moderate
81–100 55 (3.0) 29 (52.7) Moderate 501 (27.1) 197 (39.3)
>100 964 (52.1) 747 (77.5) High 964 (52.1) 747 (77.5)
Total 1851 983
Almeda et al. [23] 0 26 (10.6) 2 (7.7) Low 26 (10.6) 2 (7.7)
<100 28 (11.4) 14 (50.0) Moderate
100–399 71 (28.9) 39 (54.9) Moderate 99 (40.3) 53 (53.5)
400 121 (49.2) 105 (86.8) High 121 (49.2) 105 (86.8)
Total 246 160
Knez et al. [24] 0 254 (12.0) 13 (5.1) Low
1–9 427 (20.2) 75 (17.6) Low 681 (32.2) 88 (12.9)
10–99 211 (10.0) 150 (71.1) Moderate 211 (10.0) 150 (71.1)
>99 1223 (57.8) 1017 (83.2) High 1223 (57.8) 1017 (83.2)
Total 2115 1255
*CAD, coronary artery disease; EBCT, electron beam computed tomography.
**Here '?' denotes that the simplified EBCT category could be the adjacent category.
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BMC Medicine 2007, 5:35 http://www.biomedcentral.com/1741-7015/5/35result of the lack of access to individual-level data. For
studies of asymptomatic patients we were unable to
evaluate the change in risk over time in each category, as
information on the time of occurrence of outcomes was
not always available. Consequently, we were limited to a
crude cross-sectional type analysis based only on the
observed outcomes in each category at the end of each
study. Also incomplete study follow-up may have also
introduced bias. Finally, another possible limitation of
our work may relate to our literature search where unpub-
lished, grey literature and non-English articles were not
considered. On the other hand, our search of the conven-
tional electronic databases may be seen as thorough and
systematic.
Conclusion
We conclude that increasing calcium scores are associated
with increasing risk of CAD among both asymptomatic
and symptomatic patients. In general, it appears that
asymptomatic patients with a high EBCT score may bene-
fit from preventive interventions such as medical therapy
and risk factor modification. Similar conclusions apply to
asymptomatic patients classified as having a moderate
EBCT score. Among symptomatic patients, those with a
low EBCT score could perhaps be further evaluated with
non-invasive tests possibly avoiding angiography. How-
ever, the evidence in the literature does not allow us to
draw conclusions about the value of this technology for
individual patients, and therefore to justify its routine use.
It is especially unclear what additional value EBCT scores
provide to patients in different age-sex groups. We recom-
mend that future studies of EBCT need to: (1) use stand-
ardized cut-offs to allow for comparability; (2) adjust for
the age-sex distribution of EBCT scores in classifying indi-
viduals into risk categories; and (3) use survival analysis
techniques while reporting data from prospective studies.
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